Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Gastroenterology
Diabetes
Questions discussed in this category
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
1 Answer available
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
1 Answer available
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
1 Answer available
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
2 Answers available
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
1 Answer available
How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?
Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should...
1 Answer available
How do you counsel patients on the use of compounded weight loss medications?
3 Answers available
21947
22704
22838
22658
22111
16828
20866
Papers discussed in this category
BMC endocrine disorders, 2024 Nov 18
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.
International urology and nephrology, 2024 Nov 04
Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.
Cancers, 2024 Sep 22
Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.
The New England journal of medicine, 2015-07-02
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Annals of translational medicine, 2021 Sep
Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.
Related Topics in Gastroenterology
Radiation Oncology
Gynecologic Oncology
Palliation
Gastrointestinal Cancers
Genitourinary Cancers
Melanoma/Skin Cancer
Pediatric Hematology/Oncology
Thoracic Malignancies
Esophageal Cancer
Medical Oncology